Statistics on Biotechnology Use  
Results by sector of operation
Company sector.  Biotechnology results by main variables by whichever Biotechnology activities are the main ones, secondary or a tool necessary for production
Unidades: specified in variables

;Total;Main;Secondary dwellings;Tool;
Companies that carry out R&D in Biotechnology;1.079;519;179;381;
%Companies according to biotechnology used: Genetic code;35;46;29;23;
%Companies according to biotechnology used: Functional units;44;55;40;32;
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;26;34;24;17;
%Companies according to biotechnology used: Bioprocesses;49;42;46;61;
%Companies according to biotechnology used: Sub-cellular organisms;8;12;6;5;
%Companies according to biotechnology used: Bio-computing;23;35;15;10;
%Companies according to biotechnology used: Nanobiotechnology;15;23;13;4;
%Companies according to biotechnology used: Other;12;12;18;10;
%Company by field(s) of ultimate application of biotechnology use: Human Health;48;68;43;22;
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;21;25;15;17;
%Company by field(s) of ultimate application of biotechnology use: Food products;33;25;30;46;
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;22;22;21;22;
%Company by field(s) of ultimate application of biotechnology use: Environment;17;15;25;17;
%Company by field(s) of ultimate application of biotechnology use: Industry;15;16;20;10;
Personnel in R&D in biotechnology (no. of persons);9.795;5.614;1.560;2.621;
Personnel in R&D in biotechnology (no. of persons): Researchers;5.573;3.578;874;1.122;
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;4.222;2.036;686;1.500;
Personnel in R&D in biotechnology (no. of persons): women;5.298;3.242;813;1.243;
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;2.925;1.944;462;520;
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;2.373;1.298;352;724;
Personnel in R&D in biotechnology (FTE);6.828,6;4.507,9;873,3;1.447,5;
Personnel in R&D in biotechnology (FTE): Researchers;4.106,5;2.926,2;542,5;637,8;
Personnel in R&D in biotechnology (FTE): Technicians and assistants;2.722,1;1.581,7;330,8;809,6;
Personnel in R&D in biotechnology (FTE): women;3.811,7;2.613,9;467,5;730,3;
Personnel in R&D in biotechnology (FTE): (women) Researchers;2.190,7;1.587,2;290,9;312,7;
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;1.621;1.026,8;176,7;417,6;
Internal expenditure on R&D (thousands of euros);533.826;364.396;71.517;97.913;
1) By nature of the expense: Current expenses;492.955;336.315;63.751;92.889;
1.1) Remuneration to researchers;203.439;146.489;27.774;29.176;
1.2) Remuneration to technicians and assistants;96.850;59.163;11.408;26.279;
1.3) Other current expenses;192.666;130.663;24.568;37.434;
2) By nature of the expense: Capital expenses;40.870;28.081;7.766;5.024;
2.1) Land and buildings;7.521;3.628;3.306;587;
2.2) Equipment and instruments;32.078;23.504;4.431;4.144;
2.3) Acquisition of specific R+D software;1.270;949;28;293;
1) By origin of the funds: National funds;432.869;285.656;66.748;80.466;
1.1) Own funds;319.046;209.128;49.733;60.186;
1.2) From companies;39.253;26.512;5.269;7.473;
1.3) Public Administration funds;70.063;47.559;11.542;10.962;
1.4) From Universities;156;131;10;14;
1.5) From non profit private institutions;4.351;2.326;194;1.831;
1) By origin of the funds: Foreign funds;100.956;78.740;4.769;17.447;
2.1) From EU programmes;20.070;15.152;3.718;1.200;
2.2) Other foreign funds;80.886;63.588;1.051;16.247;
Purchase of R&D services in biotechnology (thousands of euros);138.625;109.756;20.480;8.390;
Purchase of R&D services in biotechnology (thousands of euros): In Spain;101.114;75.199;17.964;7.950;
Purchase of R&D services in biotechnology (thousands of euros): Abroad;37.512;34.557;2.515;440;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;46;57;43;33;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;13;12;15;14;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;12;14;15;8;
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;14;14;19;12;
%Companies that consider the following obstacles as very important considering biotechnology development : Lack of access to international markets;19;21;23;14;
%Companies that consider the following obstacles as very important considering biotechnology development : Lack of distribution and sales channels;19;23;22;13;
%Companies that consider the following obstacles as very important considering biotechnology development : Acceptance / public perception;18;19;16;16;
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;37;41;42;30;
%Companies that consider the following obstacles as very important considering biotechnology development : Time / cost;49;53;57;41;
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;19;21;20;16;
% Companies that have requested biotechnology patents;15;23;13;6;
Number of patents requested;466;349;74;42;
% Companies with income of an international origin related to biotechnological activities;24,9;33;14,5;18,8;
% Turnover representing income of an international origin related to biotechnological activities;0,9;11,2;0;0,3;
% Income of of an international origin related to biotechnological activities distributed in: Income received from the EU;71,3;76,7;54,2;32;
% Income of of an international origin related to biotechnological activities distributed in: Income received from other countries;28,7;23,3;45,8;68;
% Income of of an international origin related to biotechnological activities by classification: Internacional trade in products and services;92,2;92,9;56,5;92,4;
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;2,4;2,2;23,8;0,6;
% Income of an international origin related with activities according to the classification: Operating source abroad;1,3;0,9;19,7;0,7;
% Income of an international origin related with activities according to the classification: Other;4,2;4;.;6,3;
Notas:

.
'.'=numeric piece of data equal to zero not resulting from rounding 

 FTE: Full Time Equivalent
Fuente: National Statistics Institute